Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).

NCT01306929 is registered in ClinicalTrials.gov with Prilenia as lead sponsor.

NCT NCT01306929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01306929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).
Lead sponsor
Prilenia
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2011
Completion date
January 5, 2018
Enrollment
134 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

huntington disease